Sentynl Therapeutics Partners with myTomorrows for Enhanced Access to Rare Disease Treatments

Sentynl Therapeutics Partners with myTomorrows

In a significant stride towards enhancing the accessibility of treatments for rare diseases, Sentynl Therapeutics, a biopharmaceutical firm based in the United States and owned by Zydus Lifesciences, has transitioned its Managed Access Program (MAP) to the innovative platform of myTomorrows. This strategic collaboration is aimed at connecting patients with rare medical conditions to critical therapies that lie beyond conventional care offerings.

Commitment to Rare Disease Treatment

The partnership highlights Sentynl's unwavering commitment to ensuring that individuals suffering from ultra-rare conditions such as Hutchinson-Gilford Progeria Syndrome (HGPS) and processing-deficient Progeroid Laminopathies (PDPL) receive timely access to life-changing treatments. These diseases are characterized by rapid aging in children, making timely and effective therapeutic options essential.

Matt Heck, the President and CEO of Sentynl, expressed unwavering determination in the company’s mission: "It is Sentynl's mission to ensure patients with rare diseases have access to life-extending therapies. We are constantly seeking innovative approaches to enhance access for our patients. With myTomorrows’ expertise, we are poised to expand our MAP's reach while upholding the highest standards of compliance and service."

Role of myTomorrows

myTomorrows is recognized globally as a leading health technology enterprise that specializes in connecting patients suffering from serious diseases with pre-approval treatment options, including clinical trials and MAPs. Michel van Harten, CEO of myTomorrows, also voiced the company's eagerness to partner with Sentynl, emphasizing the mission to ensure no patient is barred from necessary treatments due to geographical barriers or regulatory challenges.

“myTomorrows is proud to support Sentynl in continuing to broaden the availability of treatment, ensuring that no patient is left behind due to geography or regulatory delays,” said van Harten. Their focus on offering global access solutions positions them uniquely to assist Sentynl in scaling the MAP effectively.

A Vision for Global Access

Together, Sentynl and myTomorrows are working on enhancing collaboration on additional managed access programs, leveraging myTomorrows' expertise in providing treatments for an array of rare and ultra-rare diseases. This fruitful partnership signifies both companies' vision where patients worldwide have the opportunity to access the innovative therapies they critically need.

About myTomorrows

Operating globally, myTomorrows strives to eliminate obstacles faced by patients seeking treatment options. Their proprietary technology conducts exhaustive searches of clinical trials and Expanded Access Programs from trustworthy global registries, facilitating connections between patients, healthcare providers, trial sites, and pharmaceutical companies. With headquarters in Amsterdam and an office in New York City, myTomorrows has successfully supported over 16,200 patients and 2,600 healthcare providers across more than 320 locations in 128 countries.

For further information, visit mytomorrows.com.

About Sentynl Therapeutics

Sentynl Therapeutics focuses on delivering groundbreaking therapies to individuals battling rare diseases. After being acquired by the Zydus Group in 2017, Sentynl has harnessed an experienced management team adept at building successful pharmaceutical ventures. The company is devoted to high ethical standards, addressing unmet needs through well-differentiated products spanning various therapeutic areas. To learn more, visit sentynl.com.

About Zydus Group

Zydus Lifesciences Ltd. positions itself as a transformative global lifescience firm committed to enabling healthier lives. With a substantial focus on cancer therapies, Zydus employs over 26,000 individuals, including 1,400 researchers dedicated to development. The Group embodies a mission to redefine possibilities in healthcare, aiming to make significant contributions to global health. More information can be found at zyduslife.com.